Herpesvirus saimiri-based endothelin-converting enzyme-1 shRNA expression decreases prostate cancer cell invasion and migration
✍ Scribed by Yue Hong; Stuart Macnab; Louise A. Lambert; Anthony J. Turner; Adrian Whitehouse; Badar A. Usmani
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- French
- Weight
- 948 KB
- Volume
- 129
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The zinc metalloprotease, endothelin‐converting enzyme‐1 (ECE‐1), which converts the mitogenic peptide endothelin‐1 (ET‐1) from its biologically inactive precursor big‐ET‐1, is commonly upregulated in prostate cancer (PC) cells. Consequently, we have sought to suppress ECE‐1 expression by using RNAi as a potentially novel therapeutic approach. Therefore, a synthetic 64‐nt short‐hairpin RNA (shRNA), designed to target the ECE‐1 gene, was expressed in an Herpesvirus saimiri (HVS)‐based delivery vector. ECE‐1 expression in cells transduced with the vector was examined by real‐time PCR and Western blotting. The effects of ECE‐1 knockdown on PC cell migration and invasion were studied using a scratch assay and Matrigel invasion. These studies, in vitro and ex vivo, demonstrated that the HVS‐shRNA viruses could infect and silence ECE‐1 expression effectively in human PC cells. Furthermore, it was observed that ECE‐1 knockdown in either stromal cells or epithelial cells could significantly reduce invasion of PC‐3 cells in coculture by 33 and 31%, respectively. In addition, suppressed migration was also observed in HVS‐ECE‐1 shRNA‐infected PC‐3 cells compared to uninfected and HVS‐GFP‐infected control cell cultures. These findings highlight the potential tumor‐suppressing effect of ECE‐1 knockdown in cancer cells and novel strategies for future therapeutic developments in advanced PC.